Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000608412 | SCV000712283 | likely benign | not specified | 2016-06-24 | criteria provided, single submitter | clinical testing | p.Thr198Ala in exon 7 of TRDN: This variant is not expected to have clinical sig nificance due to a lack of conservation across species, including mammals. Of no te, >5 mammals have an alanine (Ala) at this position despite high nearby amino acid conservation. In addition, computational prediction tools do not suggest a high likelihood of impact to the protein. |
Gene |
RCV001764722 | SCV001990215 | uncertain significance | not provided | 2019-07-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024893 | SCV005024486 | uncertain significance | Cardiovascular phenotype | 2024-02-22 | criteria provided, single submitter | clinical testing | The p.T198A variant (also known as c.592A>G), located in coding exon 7 of the TRDN gene, results from an A to G substitution at nucleotide position 592. The threonine at codon 198 is replaced by alanine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |